LT4259617T - Pakeistos pirazolo piperidino karboksirūgštys - Google Patents

Pakeistos pirazolo piperidino karboksirūgštys

Info

Publication number
LT4259617T
LT4259617T LTEPPCT/EP2021/084987T LTEP2021084987T LT4259617T LT 4259617 T LT4259617 T LT 4259617T LT EP2021084987 T LTEP2021084987 T LT EP2021084987T LT 4259617 T LT4259617 T LT 4259617T
Authority
LT
Lithuania
Prior art keywords
carboxylic acids
substituted pyrazole
piperidine carboxylic
pyrazole piperidine
substituted
Prior art date
Application number
LTEPPCT/EP2021/084987T
Other languages
English (en)
Lithuanian (lt)
Inventor
Alexandros Vakalopoulos
Marie-Pierre Collin-Kröpelin
Nuria Ortega Hernandez
Andre DIESKAU
Melissa BOULTADAKIS-ARAPINIS
Lisa CANDISH
Timo Stellfeld
Ilka MATHAR
Lucas Hofmeister
Peter Sandner
Frank Wunder
Lisa Dietz
Robert Webster
Carsten Schmeck
Thomas MONDRITZKI
Michael G. Hahn
Markus Follmann
Jan DREHER
Alexey Gromov
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of LT4259617T publication Critical patent/LT4259617T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/EP2021/084987T 2020-12-10 2021-12-09 Pakeistos pirazolo piperidino karboksirūgštys LT4259617T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20213020 2020-12-10
PCT/EP2021/084987 WO2022122914A1 (en) 2020-12-10 2021-12-09 Substituted pyrazolo piperidine carboxylic acids

Publications (1)

Publication Number Publication Date
LT4259617T true LT4259617T (lt) 2024-12-10

Family

ID=73793025

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/EP2021/084987T LT4259617T (lt) 2020-12-10 2021-12-09 Pakeistos pirazolo piperidino karboksirūgštys

Country Status (31)

Country Link
US (1) US20240051935A1 (enExample)
EP (1) EP4259617B1 (enExample)
JP (1) JP2023552583A (enExample)
KR (1) KR20230118144A (enExample)
CN (1) CN116710439A (enExample)
AR (1) AR124297A1 (enExample)
AU (1) AU2021393988A1 (enExample)
CA (1) CA3204495A1 (enExample)
CL (1) CL2023001632A1 (enExample)
CO (1) CO2023007335A2 (enExample)
CR (1) CR20230242A (enExample)
DK (1) DK4259617T3 (enExample)
DO (1) DOP2023000115A (enExample)
EC (1) ECSP23040828A (enExample)
ES (1) ES2997117T3 (enExample)
FI (1) FI4259617T3 (enExample)
GE (2) GEAP202316287A (enExample)
HR (1) HRP20241543T1 (enExample)
HU (1) HUE069255T2 (enExample)
IL (1) IL303296A (enExample)
JO (1) JOP20230132A1 (enExample)
LT (1) LT4259617T (enExample)
MX (1) MX2023006903A (enExample)
PE (1) PE20231501A1 (enExample)
PL (1) PL4259617T3 (enExample)
PT (1) PT4259617T (enExample)
RS (1) RS66294B1 (enExample)
SA (1) SA523441083B1 (enExample)
SI (1) SI4259617T1 (enExample)
TW (1) TW202237589A (enExample)
WO (1) WO2022122914A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4011873A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4011874A1 (en) * 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
EP4536205A1 (en) 2022-06-09 2025-04-16 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women
WO2024163561A1 (en) * 2023-01-31 2024-08-08 Invivosciences, Inc. Systems and methods for treating heart failure with preserved ejection fraction
WO2025067414A1 (zh) * 2023-09-27 2025-04-03 海思科医药集团股份有限公司 吡唑羧酸衍生物及其在医药上的应用
WO2025162280A1 (zh) * 2024-01-30 2025-08-07 海思科医药集团股份有限公司 吡唑羧酸衍生物及其在医药上的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
BRPI0816382A2 (pt) * 2007-09-06 2015-02-24 Merck Sharp & Dohme Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
UA109650C2 (xx) 2010-02-27 2015-09-25 Біс-арилзв'язані арилтриазолони та їх застосування
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
EP2632551B1 (en) * 2010-10-28 2016-07-06 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
HRP20191755T1 (hr) * 2012-09-07 2019-12-27 Boehringer Ingelheim International Gmbh Alkoksipirazoli kao aktivatori topljive gvanilat ciklaze
WO2015095515A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Sgc activators for the treatment of glaucoma
SI3215498T1 (sl) 2014-11-03 2018-11-30 Bayer Pharma Aktiengesellschaft Hidroksialkil-substituirani derivati feniltriazola in njihove uporabe
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
CN116829545A (zh) * 2020-12-10 2023-09-29 拜耳公司 取代的吡唑基哌啶羧酸
AU2021398486A1 (en) * 2020-12-10 2023-06-22 Bayer Aktiengesellschaft The use of sgc activators for the treatment of ophthalmologic diseases

Also Published As

Publication number Publication date
DOP2023000115A (es) 2023-07-16
AU2021393988A1 (en) 2023-06-22
DK4259617T3 (da) 2024-12-09
CL2023001632A1 (es) 2023-11-10
PE20231501A1 (es) 2023-09-26
CA3204495A1 (en) 2022-06-16
GEAP202316287A (en) 2023-09-11
AU2021393988A9 (en) 2024-09-19
CN116710439A (zh) 2023-09-05
JP2023552583A (ja) 2023-12-18
PL4259617T3 (pl) 2025-03-17
GEP20247649B (en) 2024-07-25
SI4259617T1 (sl) 2025-02-28
AR124297A1 (es) 2023-03-15
HUE069255T2 (hu) 2025-02-28
EP4259617B1 (en) 2024-10-23
PT4259617T (pt) 2024-12-05
EP4259617A1 (en) 2023-10-18
ECSP23040828A (es) 2023-07-31
IL303296A (en) 2023-07-01
KR20230118144A (ko) 2023-08-10
SA523441083B1 (ar) 2025-06-12
US20240051935A1 (en) 2024-02-15
RS66294B1 (sr) 2025-01-31
HRP20241543T1 (hr) 2025-01-03
WO2022122914A1 (en) 2022-06-16
FI4259617T3 (fi) 2024-11-27
MX2023006903A (es) 2023-06-26
ES2997117T3 (en) 2025-02-14
CR20230242A (es) 2023-07-19
CO2023007335A2 (es) 2023-06-09
JOP20230132A1 (ar) 2023-06-08
TW202237589A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
LT4259617T (lt) Pakeistos pirazolo piperidino karboksirūgštys
JP1739978S (ja) リモートコントローラ
JP1710041S (ja) リモートコントローラ
JP1687679S (ja) コントローラー
JP1698267S (ja) コントローラー
EP3986553C0 (en) CYCLOBUTYL CARBOXYLIC ACIDS AS LPA ANTAGONISTS
PL3938912T3 (pl) Techniki zarządzania kontrolerem pamięci
LT3411358T (lt) Pakeistas piperidino junginys ir jo naudojimas
EP4253377A4 (en) 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE
EP3759114A4 (en) HETEROBICYCLIC CARBONIC ACIDS AND SALT THEREOF
MA51433A (fr) Dérivé d'amino-méthyl pipéridine en tant qu'inhibiteur de kinase
EP4479095C0 (en) STABILIZED STEALTH LIPO-POLYAMINE ACIDS
EP4291295A4 (en) Intra-stimulus recruitment control
JP1733329S (ja) ソファー
EP4132523A4 (en) Novel n-aryl oxamic acids
EP4446051A4 (en) DIGITAL CONTROL DEVICE
EP4114846A4 (en) MICROBIAL ESTER PRODUCTION
EP3795036C0 (de) Matratzenversandeinheit
EP4255426A4 (en) Y-BOX BINDING PROTEIN 1 INHIBITORS
EP4230088A4 (en) Flat drawn wire mattress
JP1709498S (ja) 兎の置物
JP1768896S (ja) コンテンツ編集用コントローラ
UA42681S (uk) Диван кутовий
EP4519819A4 (en) HIGH RESOLUTION TRACEABILITY
JP1743372S (ja) コイル部品